First Light Asset Management LLC Sells 445,924 Shares of AtriCure, Inc. $ATRC

First Light Asset Management LLC lessened its position in AtriCure, Inc. (NASDAQ:ATRC) by 37.9% during the first quarter, Holdings Channel reports. The institutional investor owned 729,521 shares of the medical device company’s stock after selling 445,924 shares during the quarter. AtriCure comprises approximately 1.9% of First Light Asset Management LLC’s portfolio, making the stock its 17th largest holding. First Light Asset Management LLC’s holdings in AtriCure were worth $20,813,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Geneos Wealth Management Inc. acquired a new position in AtriCure during the 2nd quarter worth approximately $37,000. Smartleaf Asset Management LLC raised its holdings in shares of AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares during the last quarter. Fifth Third Bancorp bought a new stake in shares of AtriCure in the first quarter worth $51,000. Global Retirement Partners LLC bought a new stake in shares of AtriCure in the fourth quarter worth $73,000. Finally, State of Wyoming acquired a new position in AtriCure during the fourth quarter worth $75,000. Institutional investors own 99.11% of the company’s stock.

Insider Transactions at AtriCure

In related news, Director Karen Prange sold 3,000 shares of AtriCure stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $28.65, for a total transaction of $85,950.00. Following the completion of the transaction, the director owned 26,373 shares in the company, valued at approximately $755,586.45. This trade represents a 10.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ATRC. Freedom Capital upgraded shares of AtriCure to a “strong-buy” rating in a research note on Wednesday, April 1st. Canaccord Genuity Group lifted their target price on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Weiss Ratings lowered AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 4th. Raymond James Financial set a $52.00 price target on AtriCure in a research report on Tuesday, July 21st. Finally, Wall Street Zen lowered AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.12.

AtriCure News Roundup

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: Q2 earnings of $0.18 per share beat the $0.03 consensus and improved from a loss a year ago, showing a meaningful profitability turnaround. AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Revenue of $153.6 million topped Wall Street estimates of $151.8 million, reinforcing that demand remains solid. AtriCure Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company lifted FY2026 EPS guidance to $0.24-$0.32, well above the prior consensus, and revenue guidance of $602 million-$610 million is also near or slightly above expectations. AtriCure Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management described the quarter as one of “healthy growth” and a “significant step up in profitability,” which supports the recent stock strength. AtriCure Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Short-interest data showed 0 reported shares, so it does not appear to be a meaningful trading catalyst.

AtriCure Stock Performance

NASDAQ ATRC opened at $35.04 on Monday. The firm has a market capitalization of $1.77 billion, a P/E ratio of 166.87 and a beta of 1.24. The company has a current ratio of 4.29, a quick ratio of 3.18 and a debt-to-equity ratio of 0.15. The firm’s fifty day moving average price is $30.05 and its two-hundred day moving average price is $31.36. AtriCure, Inc. has a 1 year low of $25.36 and a 1 year high of $43.18.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The company had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.37%. During the same quarter last year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, research analysts anticipate that AtriCure, Inc. will post 0.13 EPS for the current year.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.